Are Robust Financials Driving The Recent Rally In Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Stock?

Hansoh Pharmaceutical Group's (HKG:3692) stock is up by a considerable 33% over the past three months. Since the market usually pay for a company’s long-term fundamentals, we decided to study the company’s key performance indicators to see if they could be influencing the market. Particularly, we will be paying attention to Hansoh Pharmaceutical Group's ROE today.

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. Put another way, it reveals the company's success at turning shareholder investments into profits.

Check out our latest analysis for Hansoh Pharmaceutical Group

How Is ROE Calculated?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Hansoh Pharmaceutical Group is:

13% = CN¥3.3b ÷ CN¥26b (Based on the trailing twelve months to December 2023).

The 'return' is the income the business earned over the last year. One way to conceptualize this is that for each HK$1 of shareholders' capital it has, the company made HK$0.13 in profit.

What Has ROE Got To Do With Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

Hansoh Pharmaceutical Group's Earnings Growth And 13% ROE

To start with, Hansoh Pharmaceutical Group's ROE looks acceptable. Further, the company's ROE is similar to the industry average of 12%. This certainly adds some context to Hansoh Pharmaceutical Group's moderate 6.0% net income growth seen over the past five years.

We then performed a comparison between Hansoh Pharmaceutical Group's net income growth with the industry, which revealed that the company's growth is similar to the average industry growth of 5.9% in the same 5-year period.

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. What is 3692 worth today? The intrinsic value infographic in our free research report helps visualize whether 3692 is currently mispriced by the market.

Is Hansoh Pharmaceutical Group Efficiently Re-investing Its Profits?

Hansoh Pharmaceutical Group has a low three-year median payout ratio of 21%, meaning that the company retains the remaining 79% of its profits. This suggests that the management is reinvesting most of the profits to grow the business.

Moreover, Hansoh Pharmaceutical Group is determined to keep sharing its profits with shareholders which we infer from its long history of three years of paying a dividend. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 21%. Accordingly, forecasts suggest that Hansoh Pharmaceutical Group's future ROE will be 13% which is again, similar to the current ROE.

Summary

Overall, we are quite pleased with Hansoh Pharmaceutical Group's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.